Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Lowered by Zacks Research

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday, Zacks reports.

Other equities research analysts have also recently issued reports about the company. Sanford C. Bernstein lifted their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Berenberg Bank set a $24.00 target price on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 29th. BNP Paribas Exane cut Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 target price for the company. in a report on Tuesday, July 28th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Seven analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Reduce” and a consensus target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.1%

NYSE FMS traded up $0.03 on Thursday, reaching $22.16. The stock had a trading volume of 620,732 shares, compared to its average volume of 1,011,595. The firm has a market capitalization of $11.90 billion, a price-to-earnings ratio of 11.48, a P/E/G ratio of 4.09 and a beta of 0.74. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $27.43. The stock has a fifty day moving average price of $22.65 and a two-hundred day moving average price of $22.88.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. The company had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. As a group, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently modified their holdings of the stock. Pzena Investment Management LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after purchasing an additional 299,986 shares during the period. Royal Bank of Canada increased its holdings in Fresenius Medical Care AG & Co. KGaA by 479.2% during the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock worth $4,893,000 after purchasing an additional 179,418 shares during the period. Assetmark Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 190.7% during the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock worth $2,985,000 after purchasing an additional 86,798 shares during the period. Moran Wealth Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock valued at $7,846,000 after purchasing an additional 83,311 shares in the last quarter. Finally, Ritholtz Wealth Management raised its position in Fresenius Medical Care AG & Co. KGaA by 252.7% in the 1st quarter. Ritholtz Wealth Management now owns 84,658 shares of the company’s stock valued at $1,910,000 after purchasing an additional 60,652 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.